Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC
home / news-network / immune-checkpoint-inhibitors-in-first-line-treatment-of-metastatic-nsclc
Hossein Borghaei, DO, MS, and Martin Reck, MD, PhD, highlight recent advances and use of immune checkpoint inhibitors in the treatment of first-line metastatic non-small cell lung cancer.